Contents

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Show Summary Details
Page of

Index 

Index
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 04 August 2021

A
A-a (alveolar-to-arterial) gradient, [link]
ABCD2 score, [link]–[link]
abciximab, [link]
abdominal pain
approach to patient with, [link]–[link]
causes of, [link]
in DKA evaluation, [link]
recommendations for managing patients with, [link]
ablation, for atrial fibrillation, [link]
ABPA (allergic bronchopulmonary aspergillosis), [link]
absence seizures, [link]–[link]
absolute polycythemia, [link]–[link]
absorption abnormalities, [link]
AC (assist control), [link]
ACC/AHA (American College of Cardiology/American Heart Association) Staging System, [link]
ACD (anemia of chronic disease), [link]
ACE (angiotensin-converting enzyme) inhibitors. See [link]
acetaminophen
acute liver failure due to, [link], [link], [link]
in fever management, [link]
overdose, [link]–[link]
for pain treatment in dying patients, [link]
acid-base disorders
described, [link]
differential diagnosis of
metabolic acidosis, [link]–[link]
metabolic alkalosis, [link]–[link]
evaluation of, steps in, [link]–[link]
acidemia, [link]–[link]
acid-fast bacillus stain, [link]
acidosis
alcoholic ketoacidosis, [link], [link]–[link]
anion gap, [link]
diabetic ketoacidosis, [link], [link]–[link]
dialysis in management of, [link]
due to inorganic acids, [link]
lactic, [link]
metabolic
acute dyspnea and, [link]
acute liver failure and, [link]
differential diagnosis of, [link], [link]–[link]
evaluation of, [link]–[link]
hyperkalemia and, [link]
nonanion gap, [link]
post-anion gap, [link]
renal tubular, [link], [link]
respiratory, [link], [link], [link]
acidosis-induced hyperkalemia, [link]
ACOS (asthma-COPD overlap syndrome), [link]
acquired clotting disorders, [link]–[link]
acquired clubbing, [link]
acquired platelet dysfunction, [link]–[link]
acquired storage pool disease, [link]
ACS. See [link]
ACTH (cosyntropin) stimulation test, [link]
Actinomyces, [link]
activated charcoal, [link]–[link], [link], [link]
acute adrenal insufficiency, [link], [link]
acute axonal polyneuropathies, [link]
acute bacterial endocarditis, [link]
acute bacterial meningitis, [link], [link], [link]
acute coronary syndrome (ACS)
approach to patient with, [link]–[link]
clinical manifestations of, [link]
complications of, [link]–[link]
diagnosis of, [link]–[link]
overview, [link]
pathophysiology of, [link]
post-hospitalization and long-term management of, [link]–[link]
acute demyelinating polyneuropathies, [link]
acute dialysis, [link]
acute diarrhea
approach to patient with, [link]–[link]
classification of, [link]
defined, [link]
in hospitalized patients, common causes of, [link]
treatment of, [link]
acute dyspnea
approach to patient with, [link]
causes of, [link]
defined, [link]
treatment of, [link]
acute endocarditis, [link]
acute glomerulonephritis, [link], [link], [link], [link]
acute heart failure (HF), [link]–[link]
acute hepatitis, [link]
acute inflammatory demyelinating polyradiculoneuropathy (AIDP), [link]–[link]
acute intermittent porphyria, [link]
acute interstitial nephritis, [link], [link]
acute kidney injury (AKI)
approach to patient with, [link]–[link]
causes of, [link]–[link]
clinical manifestations of, [link]
defined, [link]
epidemiology of, [link]
treatment of, [link]–[link]
acute leukemia
approach to patient with, [link]–[link]
classification of, [link]–[link]
clinical manifestations of, [link]–[link]
complications associated with, [link]–[link]
described, [link]
epidemiology of, [link]
MDS and, [link]
risk factors for, [link]
treatment of, [link]–[link]
acute liver failure
causes of, [link]–[link]
clinical manifestations of, [link]–[link]
defined, [link]
treatment of, [link]
acute lymphoblastic leukemia (ALL)
approach to patient with, [link]–[link]
clinical manifestations of, [link]–[link]
complications associated with, [link]–[link]
described, [link]–[link]
epidemiology of, [link]
risk factors for, [link]
treatment of, [link]–[link]
acute mitral regurgitation, from ACS, [link]–[link]
acute myeloid leukemia (AML)
approach to patient with, [link]–[link]
clinical manifestations of, [link]–[link]
complications associated with, [link]–[link]
described, [link]
epidemiology of, [link]
risk factors for, [link]
treatment of, [link]–[link]
acute pancreatitis
approach to patient with, [link]
causes of, [link]–[link]
clinical manifestations of, [link]
complications of, [link]
defined, [link]
treatment of, [link]–[link]
acute respiratory distress syndrome (ARDS), [link]
acute rheumatic fever
defined, [link]
described, [link]
diagnosis of, [link]–[link]
epidemiology of, [link]
polyarthritis due to, [link]
treatment of, [link]
acute splenomegaly, [link]–[link]
acute tubular necrosis (ATN), [link], [link]–[link], [link]
acyclovir
HIV-related viral esophagitis, [link]
in meningitis management, [link]
Addison’s disease
causes of, [link]
clinical manifestations of, [link]
eosinophilia due to, [link]
hypercalcemia due to, [link]
ADE. See [link]
adenosine
in angina evaluation, [link]
for narrow, regular tachycardia, [link]
for VT, [link]
ADH. See [link]
administration errors, [link]
adrenal crisis, [link], [link]
adrenal disease, hypercalcemia due to, [link]
adrenal insufficiency
approach to patient with, [link]
causes of, [link]
clinical manifestations of, [link]–[link]
definitions, [link]
primary, [link], [link], [link]
secondary, [link], [link]–[link], [link]
tertiary, [link], [link]
treatment of, [link]–[link]
adult-onset Still’s disease (AOSD), [link], [link]–[link]
adverse drug event (ADE)
definition, [link]
incidence of, [link]
prevention of
administration errors, [link]–[link]
anticipation of complications, [link]
dispensing errors, [link]
medication information, [link]–[link]
ordering, [link]–[link]
adverse events, defined, [link]
AEDs (antiepileptic drugs), [link]–[link]
aerobic gram-negative rods, [link]
AIDP (acute inflammatory demyelinating polyradiculoneuropathy), [link]–[link]
AIDS-associated enteropathy, [link]
AIDS cholangiopathy, [link]
AIHA (autoimmune hemolytic anemia), [link], [link]
airflow limitation, [link]
AKA (alcoholic ketoacidosis), [link], [link]–[link]
AKI. See [link]
albuterol, in hyperkalemia management, [link]
alcohol abuse
acute pancreatitis due to, [link]
alcohol intoxication, [link]–[link]
alcohol withdrawal, [link]–[link]
alcoholic hepatitis, [link]–[link]
alcoholic ketoacidosis (AKA), [link], [link]–[link]
alcoholic liver disease
approach to patient with, [link]–[link]
clinical manifestations of, [link]
described, [link]
treatment of, [link]–[link]
alcoholism
approach to patient with, [link]
detection of, [link]
ESLD due to, [link]
macrocytic anemia due to, [link]
alcohol use, hospitalization and, [link]
aldosterone antagonists
in ACS management, [link]
in chronic HFrEF management, [link]
alkalemia, [link], [link]
alkali ingestion, hypercalcemia due to, [link]
alkalosis
metabolic, [link], [link], [link]–[link]
respiratory, [link], [link], [link]–[link]
alkylating agents
in ET management, [link]
in PV management, [link]
ALL. See [link]
allergic bronchopulmonary aspergillosis (ABPA), [link]
allergic disorders, eosinophilia due to, [link]
allergic interstitial nephritis, [link]
allodynia, [link]
allogeneic bone marrow transplantation
in AML management, [link]
in CML management, [link]
complications of, [link]
in MDS management, [link]
in PMF management, [link]
alopecia areata, [link]–[link]
altered mental status
acute dyspnea evaluation, [link]
acute liver failure and, [link]–[link]
approach to patient with, [link]–[link]
causes of, [link]
definitions, [link]
from meningitis, [link]
alveolar gas equation, [link]
alveolar infiltrates, [link]
alveolar proteinosis, [link]
alveolar-to-arterial (A-a) gradient, [link]
amebiasis, FUO due to, [link]
American College of Cardiology/American Heart Association (ACC/AHA) Staging System, [link]
amiodarone
for atrial fibrillation, [link], [link]
for VT, [link]
AML. See [link]
amlodipine, in angina management, [link]
amoxicillin, in cystitis management, [link]
amphetamine overdose, [link]
ampicillin, in meningitis management, [link]
amyloid, nephrotic syndrome due to, [link]
amyloidosis, in multiple myeloma evaluation, [link]
anaerobe(s), [link]
anagrelide
in ET management, [link]
in thrombocytosis management, [link]
analgesic(s), nonopioid, in pain management, [link]
anaphylactic shock, [link]
anasarca, [link]
anatomic renal tubular defects, [link]
anemia of chronic disease (ACD), [link]
anemia(s)
acute dyspnea and, [link]
acute leukemia and, [link]
aplastic, [link], [link]
classification, [link]
clinical manifestations of, [link]
defined, [link]
iron deficiency, [link], [link], [link], [link]
macrocytic, [link]
megaloblastic, [link]
microcytic, [link]–[link]
in multiple myeloma evaluation, [link]
normocytic, [link]–[link]
pancytopenia and, [link], [link]
sideroblastic, [link]
anesthesia/anesthetics, [link], [link]
angina
anginal equivalents, [link]
approach to patient with, [link]–[link]
atherosclerosis, risk factors for, [link]
coronary artery disease, clinical manifestations of, [link]–[link]
defined, [link]
stable, [link]
stress tests, [link]–[link]
treatment of, [link]–[link]
unstable, [link]–[link]
angiodysplasia, [link]
angiography
coronary
in ACS management, [link]
cardiac catheterization with, [link]
CT
in angina evaluation, [link]
in pulmonary embolism evaluation, [link], [link]
in stroke evaluation, [link]
MRA, in stroke evaluation, [link]
pulmonary, in pulmonary embolism evaluation, [link]
angiotensin-converting enzyme (ACE) inhibitors
in ACS management, [link]–[link]
in angina management, [link]
in chronic HFrEF management, [link]
hyperkalemia from, [link]
in hypertension management, [link]
in polycythemia management, [link]
angiotensin receptor blockers (ARBs)
in ACS management, [link]–[link]
in angina management, [link]
in chronic HFrEF management, [link]
in hypertension management, [link]
angiotensin receptor-neprilysin inhibitor (ARNI), in chronic HFrEF management, [link]
animal bites, [link], [link]–[link]
anion gap
calculating, [link]–[link]
in multiple myeloma evaluation, [link]
anion gap acidosis, [link], [link]
ankle-foot orthotics, [link]
Ann Arbor classification system, [link], [link]
antacid medications, [link]
anterior wall myocardial infarction, [link]
antiarrhythmic therapy, for atrial fibrillation, [link]
antibiotic(s)
in acute diarrhea management, [link]
in acute rheumatic fever management, [link]
in cystitis management, [link]
in fever management, [link]–[link]
in obstructive lung disease management, [link]
in pancytopenia management, [link]
antibody tests, [link]
anticholinergics
for dyspnea, [link]
for nausea and vomiting, [link]
toxicity of, [link]
anticoagulant(s)
in ACS management, [link]
for atrial fibrillation, [link]–[link]
for hypercoagulable states, [link]–[link]
in PNH management, [link]
in pulmonary embolism management, [link]
anticonvulsant(s), in pain management, [link]
antidepressant(s)
for anxiety in dying patients, [link]
for depression in dying patients, [link]
TCAs
in neuropathic pain management, [link]
overdose, [link]–[link]
for pain treatment in dying patients, [link]
antidiuretic hormone (ADH)
described, [link]
SIADH, [link]
antidotes, [link]
antidromic conduction, [link]
antiepileptic drugs (AEDs), [link]–[link]
anti-GBM-associated diseases, [link]
antihistamine(s)
for nausea and vomiting, [link]
in pruritus management, [link]
antimicrobial therapy
described, [link]
surgical debridement with, for necrotizing soft tissue infection, [link]
antimotility agents, in acute diarrhea management, [link]
antiphospholipid antibodies, [link], [link]
antiphospholipid antibody syndrome, [link], [link]–[link]
antiplatelet therapy, in ACS management, [link]
antipsychotic(s), for anxiety in dying patients, [link]
antipyretic therapy, in fever management, [link]
antithrombin deficiency, [link]–[link]
antithymocyte globulin, in aplastic anemia management, [link]
anxiety
acute dyspnea from, [link]
in dying patients, management of, [link]
aortic coarctation, hypertension due to, [link]
aortic dissection
chest radiographs, approach to, [link]
screening for, [link]–[link], [link]
syncope due to, [link]
aortic stenosis, AKI due to, [link]
AOSD (adult-onset Still’s disease), [link], [link]–[link]
apical pneumothoraces, [link]
apices, in chest radiographs, [link]
apixaban, for atrial fibrillation, [link]
aplastic anemia
pancytopenia due to, [link]
thrombocytopenia due to, [link]
treatment of, [link]
apnea, in dying patients, [link]
ARBs. See [link]
ARDS (acute respiratory distress syndrome), [link]
ARNI (angiotensin receptor-neprilysin inhibitor), in chronic HFrEF management, [link]
arrhythmias. See also [link]
ACS complications, [link]–[link]
acute dyspnea and, [link]
atrial flutter, [link], [link]–[link]
atrial tachycardia, [link]–[link], [link]
bradyarrhythmias, [link]
CHF and, [link]
sinus tachycardia, [link]–[link], [link], [link]
syncope from, [link]
tachyarrhythmias, [link]
narrow, irregular, [link]
narrow, regular, [link]–[link]
wide, irregular, [link]–[link]
wide, regular, [link]–[link]
ventricular tachycardia, [link]
arterial blood gases
in chest pain evaluation, [link]
in pulmonary embolism evaluation, [link]
sampling procedure, [link]–[link]
arterial catheter placement, [link]–[link]
arterial oxygen tension (PaO2), [link]
arteriography, in massive hemoptysis evaluation, [link]
arteriovenous malformations
GI bleeding due to, [link]
hemoptysis due to, [link]
arteritis
Takayasu’s, [link]
temporal, [link]–[link]
arthralgias, [link]
arthritis
in acute rheumatic fever evaluation, [link]
in AOSD, [link]
approach to diagnosis, [link]–[link]
history taking, [link]–[link]
imaging in evaluation of, [link]–[link]
laboratory testing of blood, [link]
laboratory testing of joint fluid, [link]–[link]
monoarthritis, [link]–[link]
oligoarthritis, [link]–[link]
overview of, [link]
physical examination, [link]
polyarthritis, [link]–[link]
arthrocentesis, [link]–[link]
ascending aortic dissection, [link]
ascites
approach to patient with, [link]–[link]
causes of, [link]
defined, [link]
ESLD and, [link]
treatment of, [link]
aseptic meningitis, [link], [link], [link]
aspergillosis
FUO due to, [link]
hemoptysis due to, [link]
aspiration, acute dyspnea due to, [link]
aspirin
acquired platelet dysfunction due to, [link]
in ACS management, [link]
in angina management, [link]
for atrial fibrillation, [link]
in ET management, [link]
in ischemic infarction management, [link]
perioperative management of, [link], [link]
in PV management, [link]
salicylate toxicity, [link]
in thrombocytosis management, [link]–[link]
assist control (AC), [link]
asterixis, acute liver failure and, [link]
asthma
clinical manifestations of, [link]
defined, [link]
diagnosis of, [link]
treatment of, [link]
asthma-COPD overlap syndrome (ACOS), [link]
asymmetric breath sounds, in shock evaluation, [link]
asymptomatic bacteriuria, [link]
AT (atrial tachycardia), [link]–[link], [link]
atenolol, in angina management, [link]
atherosclerosis
nephrotic syndrome and, [link]
risk factors for, [link]
ATN (acute tubular necrosis), [link], [link]–[link], [link]
atopic dermatitis, [link]
atorvastatin, [link]
atrial fibrillation
with aberrancy, [link]–[link]
approach to patient with, [link]
causes of, [link]–[link]
classification of, [link]
clinical manifestations of, [link]–[link]
complications of, [link]
epidemiology of, [link]
overview, [link]
pathophysiology of, [link]
thromboembolic risk reduction, therapy for, [link]–[link]
treatment of, [link]–[link]
atrial flutter
described, [link]
treatment of, [link], [link]–[link]
with variable block, [link]
atrial tachycardia (AT), [link]–[link], [link]
atrioventricular (AV) nodal blocking agents, for atrial fibrillation, [link]–[link], [link]
atrioventricular nodal reentrant tachycardia (AVNRT), [link]–[link], [link], [link]
atrioventricular reentrant tachycardia (AVRT), [link]–[link], [link], [link]
atropine
for bradyarrhythmias related to ACS, [link]
for cholinergic agonist toxicity, [link]
aura, [link]
autoimmune hemolytic anemia (AIHA), [link], [link]
autoimmune hepatitis, [link], [link]
autoimmune myositis, [link]–[link]
autoimmune parathyroid destruction, [link]–[link]
autoimmune thrombotic disease, [link]
autoinflammatory diseases, [link]
autologous bone marrow transplantation, in multiple myeloma management, [link]
automatism(s), [link]
autonomic failure, [link]
autonomous toxic adenomas, [link]
AV (atrioventricular) nodal blocking agents, for atrial fibrillation, [link]–[link], [link]
avascular necrosis
MRI in evaluation of, [link]
radionuclide bone scan in evaluation of, [link]
AVNRT (atrioventricular nodal reentrant tachycardia), [link]–[link], [link], [link]
AVRT (atrioventricular reentrant tachycardia), [link]–[link], [link], [link]
axial arthritis
MRI in evaluation of, [link]
radiographs for, [link]
axis interpretation in EKGs, [link]–[link]
azacitidine (Vidaza), [link]


B
Bacillus, [link]
back pain, spinal cord compression and, [link]
backward heart failure, [link]
bacteremia(s), FUO due to, [link]
bacterial endocarditis, [link], [link]
bacterial infections
exanthems due to, [link]
FUO due to, [link]
in HIV infected patients, [link]
HIV-related enterocolitis from, [link]
HIV-related meningitis due to, [link], [link]
lymphadenopathy due to, [link]
pulmonary infiltrates in HIV, differential diagnosis of, [link]
rashes from, [link]
splenomegaly due to, [link]
bacterial meningitis, acute, [link], [link], [link]
bacteriuria, asymptomatic, [link]
β‎-agonist(s)
in acute dyspnea management, [link]
hyperkalemia and, [link]
BAL (blood alcohol level), [link]–[link]
banana bag, [link]
Bartter’s syndrome, [link], [link]
basophilia, [link]
β‎-blockers
in ACS management, [link]
in alcohol withdrawal management, [link]
in angina management, [link]–[link]
anxiety management in dying patients, [link]
for atrial fibrillation, [link]
in chronic HFrEF management, [link]
in perioperative risk reduction strategies, [link]
bedsores, [link]
Behçet’s syndrome, [link]–[link]
benzodiazepine(s)
in alcohol withdrawal management, [link]
for anxiety in dying patients, [link]
for nausea and vomiting, [link]
for phenothiazine overdose, [link]
in stimulant overdose management, [link]
Berger’s disease, [link]
Bernard-Soulier syndrome, [link], [link]
bicarbonate, in hyperkalemia management, [link]
biliary obstruction, extrahepatic, [link]
biliary stones, acute pancreatitis due to, [link]
biomarkers, in pulmonary embolism evaluation, [link]
biopsy(ies)
bone marrow
in acute leukemia evaluation, [link]
in CML evaluation, [link]
in ET evaluation, [link]
in lymphocytosis evaluation, [link]
in MDS evaluation, [link]
in pancytopenia evaluation, [link]–[link]
in PMF evaluation, [link]
in PV evaluation, [link]
in thrombocytopenia evaluation, [link]
in thrombocytosis evaluation, [link]
in FUO evaluation, [link]
in Hodgkin’s lymphoma evaluation, [link]
liver
in acute liver failure evaluation, [link]
in HIV-related hepatobiliary disease evaluation, [link]
in non-Hodgkin’s lymphoma evaluation, [link]
peritoneal, in ascites evaluation, [link]
renal, in AKI evaluation, [link]
stereotactic brain, in space-occupying lesion evaluation, [link]
sural nerve, in polyneuropathy evaluation, [link]
surgical lung, in ILD evaluation, [link]
transbronchial, in ILD evaluation, [link]
bismuth subsalicylate, in acute diarrhea management, [link]
bisphosphonate(s)
in multiple myeloma management, [link]
for pain treatment in dying patients, [link]
bite(s), animal, [link], [link]–[link]
bladder neck obstruction, AKI due to, [link]
bladder pathology, dysuria and, [link]
blanchable erythema, [link]
blast cells
in acute leukemia evaluation, [link]
in pancytopenia evaluation, [link]
bleeding
acute GI
approach to patient with, [link]–[link]
causes of, [link]–[link]
classification of, [link]
definitions, [link]
in multiple myeloma evaluation, [link]
stress-related UGIB, [link]
variceal, management of, [link]–[link]
bleeding disorders
approach to patient with, [link]–[link]
PFA-100 in, [link]–[link]
platelet count in, [link]
PT/PTT in, [link]–[link]
clinical manifestations of, [link]
described, [link]
treatment of, [link]–[link]
blood alcohol level (BAL), [link]–[link]
blood cultures
in fever evaluation, [link]
in HIV-related enterocolitis evaluation, [link]
in infective endocarditis evaluation, [link]
in meningitis evaluation, [link]
blood pressure
hypokalemia and, [link]–[link]
in shock evaluation, [link]
blood smears, in FUO evaluation, [link]
blood urea nitrogen (BUN)
in DKA evaluation, [link]
in thrombocytopenia evaluation, [link]
BNI (brief negotiated interview), [link]
body fluid analysis, in fever evaluation, [link]
body temperature, normal, [link]
bone marrow biopsy
in acute leukemia evaluation, [link]
in CML evaluation, [link]
in ET evaluation, [link]
in FUO evaluation, [link]
in Hodgkin’s lymphoma evaluation, [link]
in lymphocytosis evaluation, [link]
in MDS evaluation, [link]
in pancytopenia evaluation, [link]–[link]
in PMF evaluation, [link]
in PV evaluation, [link]
in thrombocytopenia evaluation, [link]
in thrombocytosis evaluation, [link]
bone marrow disorders, thrombocytopenia due to, [link]
bone marrow transplantation
in ALL management, [link]
allogeneic
in AML management, [link]
in CML management, [link]
in MDS management, [link]
in PMF management, [link]
in aplastic anemia management, [link]
autologous, in multiple myeloma management, [link]
complications of, [link]
in PNH management, [link]
bone(s)
metastasis to, [link]–[link]
outside-in radiograph approach for, [link]
pain in, FUO and, [link]
bony lesions, in Waldenström’s macroglobulinemia evaluation, [link]
Bordetella pertussis, [link]
bradyarrhythmia(s), [link], [link]
bradycardia, [link]
brain, metastasis to, [link]
BRAT diet, [link]
bridging therapy, [link]
brief negotiated interview (BNI), [link]
bronchiectasis, massive hemoptysis and, [link]
bronchitis
chronic, [link]
massive hemoptysis and, [link]
bronchodilators
for dyspnea, [link]
in obstructive lung disease management, [link]
bronchoscopy
in FUO evaluation, [link]
in ILD evaluation, [link]
Brucella, [link]
Brudzinski’s sign, [link]
Brugada criteria, [link]–[link]
bubble study, in pulmonary hypertension evaluation, [link]
Budd-Chiari syndrome, [link], [link], [link]
Buerger’s disease, [link]
bullae, [link]
BUN. See [link]
bundle branch block, [link]
butterfly rash, [link]–[link]


C
CABG (coronary artery bypass grafting), [link]
calcium-channel blockers (CCBs)
in ACS management, [link]
in angina management, [link]
nondihydropyridine, for atrial fibrillation, [link]
calcium gluconate, intravenous, [link]
calcium pyrophosphate deposition (CPPD) disease, [link]
Campylobacter, [link]
CA-MRSA (community-acquired MRSA), [link], [link]
cancer
acquired platelet dysfunction due to, [link]
ascites due to, [link]
HIV-related meningitis due to, [link], [link]
hypercoagulable states due to, [link]
lymphadenopathy due to, [link]
massive hemoptysis and, [link]
metastatic neoplasms, [link]–[link]
pruritus due to, [link]
splenomegaly due to, [link]
candida esophagitis, [link]
candidiasis
FUO due to, [link]
in HIV infected patients, [link]–[link]
CAP (community-acquired pneumonia), [link]
capillary permeability, [link], [link]
Caprini Risk Score, [link]
CAPS (catastrophic antiphospholipid syndrome), [link]
capsule endoscopy, [link]
carboxyhemoglobinemia, polycythemia due to, [link], [link]
carcinoma of unknown primary (CUP), [link]
cardiac amyloidosis, [link]
cardiac auscultation, in shock evaluation, [link]
cardiac biomarker studies, in ACS evaluation, [link]
cardiac borders, outside-in radiograph approach for, [link]
cardiac catheterization with coronary angiography, [link]
cardiac disease, clubbing due to, [link]
cardiac echocardiography, [link]
cardiac resynchronization therapy (CRT), [link]
cardiac silhouette, [link]
cardiac tamponade
from ACS, [link]
acute dyspnea and, [link]
cardiogenic shock, [link], [link], [link], [link]
cardiomyopathies
dilated, [link]
inherited, [link]
restrictive, [link]
cardiovascular disease, Hodgkin’s lymphoma and, [link]
cardiovascular risk in non-cardiac surgery
perioperative risk reduction strategies, [link]–[link]
preoperative assessment of, [link]–[link]
cardiovascular syncope, [link], [link]
carotid Doppler ultrasound, [link]
carotid sinus massage, [link], [link]
carotid sinus syncope, [link]
CARP (Coronary Artery Revascularization Prophylaxis) Trial, [link]
catastrophic antiphospholipid syndrome (CAPS), [link]
catheter-associated urinary tract infection (CAUTI), [link]
catheterization
in AKI management, [link]
arterial placement, [link]–[link]
femoral central venous placement, [link]–[link]
peripheral intravenous placement, [link]
CAUTI (catheter-associated urinary tract infection), [link]
CCBs. See [link]
CD4 count
differential diagnoses according to, [link]–[link]
in FUO evaluation, [link]
in space-occupying lesion evaluation, [link]
C. difficile infection
in HIV-related enterocolitis evaluation, [link]–[link]
hospital-acquired complications, [link]
ceftriaxone, in meningitis management, [link]
ceiling effect, [link]
cellulitis, [link]–[link]
central diabetes insipidus (DI), [link]
central line-associated bloodstream infection (CLABSI), [link]
central nervous system (CNS) disorders/injury, electrocardiogram changes due to, [link]
central nervous system (CNS) prophylaxis
in ALL management, [link]
in AML management, [link]
central venous catheters (CVCs)
central line-associated bloodstream infection, [link]
venous thromboembolism, [link]–[link]
central vertigo, [link]–[link], [link]
cephalization, [link]
cerebral edema, acute liver failure and, [link]
cerebrospinal fluid (CSF) analysis
in acute leukemia evaluation, [link]
in fever evaluation, [link]
in meningitis evaluation, [link]–[link]
chamber enlargement, [link]
charcoal, activated, [link]–[link], [link], [link]
chemotherapy
for acute leukemia, [link]
for ALL, [link]–[link]
for AML, [link]
dysuria and, [link]
for Hodgkin’s lymphoma, [link]
for MDS, [link]
for multiple myeloma, [link]–[link]
for spinal cord compression, [link]
chest pain. See also [link]
from ACS, [link]
approach to patient with, [link]–[link]
cause of, defining, [link]–[link]
killer chest pains, screening for, [link]–[link]
MI and, [link]
outside-in approach to cause of, [link]
overview, [link]
pulmonary embolism and, [link]
chest radiographs
for abdominal pain evaluation, [link]
in acute leukemia evaluation, [link]
in fever evaluation, [link]
in Hodgkin’s lymphoma evaluation, [link]
in ILD evaluation, [link]
in massive hemoptysis evaluation, [link]
outside-in approach to, [link]
in pleural effusion evaluation, [link]
in polyneuropathy evaluation, [link]
preliminary considerations, [link]
preoperative testing, [link]
pulmonary disease evaluation in HIV-infected patients, [link]
in pulmonary embolism evaluation, [link]
in pulmonary hypertension evaluation, [link]
chest wall examination, chest pain and, [link]
CHF. See [link]
Chlamydiae, [link]
chloramphenicol, in meningitis management, [link]
cholestatic drugs, pruritus due to, [link]
cholestatic liver injury pattern, [link]
cholesterol embolization, eosinophilia due to, [link]
cholinergic agonist toxicity, [link]–[link]
chronic bronchitis, [link]
chronic eosinophilic leukemia, [link]
chronic glomerulonephritis, [link]
chronic hepatitis, [link], [link]
chronic hypoxemia, pulmonary hypertension and, [link]
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), [link]
chronic insufficiency, [link]
chronic liver disease, macrocytic anemia due to, [link]
chronic meningitis, [link], [link]–[link]
chronic myeloid leukemia (CML), [link], [link], [link]–[link]
chronic obstructive pulmonary disease (COPD)
clinical manifestations of, [link]
defined, [link]
diagnosis of, [link]
left axis deviation, [link]
perioperative pulmonary risks due to, [link], [link]
treatment of, [link]
chronic pancreatitis, [link]
chronic renal disease, hypercoagulable states due to, [link]
chronic thromboembolic pulmonary hypertension (CTEPH), [link]
Churg-Strauss syndrome, [link], [link]
Chvostek’s sign, [link]
chylous ascites, [link]
CIDP (chronic inflammatory demyelinating polyradiculoneuropathy), [link]
CIN (contrast-induced nephropathy), [link]–[link]
cirrhosis
alcoholic liver disease, [link], [link], [link]
ascites due to, [link]
primary biliary, pruritus due to, [link]
CJD (Creutzfeldt-Jacob disease), [link]
CK-myocardial band (CK-MB), in ACS evaluation, [link]
CLABSI (central line-associated bloodstream infection), [link]
clopidogrel, [link]
Clostridium, [link]
Clostridium difficile colitis, [link], [link]
clot prophylaxis, [link]
clubbing
approach to patient with, [link]
causes of, [link]
clinical manifestations of, [link]
described, [link]
treatment of, [link]
CML (chronic myeloid leukemia), [link], [link], [link]–[link]
CMV. See [link]
CNS (central nervous system) disorders/injury, electrocardiogram changes due to, [link]
CNS prophylaxis, [link]. See [link]
coagulation factor deficiency, [link], [link]
coagulation factor inhibitor, [link]–[link], [link]
coagulation tests, in acute leukemia evaluation, [link]
coagulopathy
hemoptysis and, [link]
liver failure and, [link]
cocaine
overdose of, [link]
vasculitis-like syndrome due to, [link]
cocci
gram-negative, [link]
gram-positive, [link]
coccidioidomycosis
eosinophilia due to, [link]
FUO due to, [link]
HIV infections and, [link]
Cogan’s syndrome, [link]
collagen vascular disease
ILD due to, [link]
splenomegaly due to, [link]
colonoscopy, in GI bleeding management, [link]
combination pain, in dying patients, [link]
combined ventilator modes, [link]
comfort care, [link]
common faint, [link]
communication
with family, during dying process, [link]–[link]
with patients, [link]
community-acquired MRSA (CA-MRSA), [link], [link]
community-acquired pneumonia (CAP), [link]
complement-mediated cell lysis, [link]
compression Doppler ultrasonography, in pulmonary embolism evaluation, [link]
computed tomography (CT)
for abdominal pain evaluation, [link]
aortic dissection, diagnosing, [link]
in arthritis evaluation, [link]
in ascites evaluation, [link]
in fever evaluation, [link]
in FUO evaluation, [link]
in HIV-related hepatobiliary disease evaluation, [link]
in massive hemoptysis evaluation, [link]
in polyneuropathy evaluation, [link]
in space-occupying lesion evaluation, [link]–[link]
in spinal cord compression evaluation, [link]
in UTI evaluation, [link]
computed tomography (CT) angiography
in angina evaluation, [link]
in pulmonary embolism evaluation, [link], [link]
in stroke evaluation, [link]
congenital heart disease
left axis deviation, [link]
right axis deviation, [link]
congenital storage pool diseases, [link], [link]
congenital thrombocytopenia, [link]
congestive heart failure. See [link]
conjugated bilirubin, [link]
connective tissue diseases. See [link]
consolidation therapy, in acute leukemia management, [link], [link]
constipation, in dying patients, management of, [link]–[link]
constrictive pericarditis, ascites due to, [link], [link]
continuous positive airway pressure (CPAP), [link]
contrast dye, AKI due to, [link]
contrast-induced nephropathy (CIN), [link]–[link]
Coombs test, [link]
COPD. See [link]
core biopsy
in Hodgkin’s lymphoma evaluation, [link]
in non-Hodgkin’s lymphoma evaluation, [link]
Cornell Criteria, [link]
coronary angiography
in ACS management, [link]
cardiac catheterization with, [link]
coronary artery bypass grafting (CABG), [link]
coronary artery bypass surgery, in angina management, [link]–[link]
coronary artery disease
antiarrhythmic therapy, [link]
clinical manifestations of, [link]–[link]
Coronary Artery Revascularization Prophylaxis (CARP) Trial, [link]
cor pulmonale, [link]
corticosteroid(s)
for fatigue in dying patients, [link]
perioperative management of, [link]–[link]
polycythemia due to, [link]–[link]
Corynebacterium, [link]
C. diphtheriae, [link]
C. jeikeium, [link]
cosyntropin (ACTH) stimulation test, [link]
cough, chronic, [link]
Coumadin skin necrosis, [link]
COURAGE trial, [link]
CPAP (continuous positive airway pressure), [link]
CPPD (calcium pyrophosphate deposition) disease, [link]
creatine kinase
in ACS evaluation, [link]
in AKI evaluation, [link]
creatinine
in DKA evaluation, [link]
in multiple myeloma evaluation, [link]
in thrombocytopenia evaluation, [link]
crepitus, [link]
Creutzfeldt-Jacob disease (CJD), [link]
CRT (cardiac resynchronization therapy), [link]
cryoablation ablation, for atrial fibrillation, [link]
cryoglobulinemia, [link], [link]
cryoprecipitate, in bleeding disorder management, [link]
cryptococcosis, [link]
Cryptococcus species infection, [link]
crystal arthritis, [link], [link], [link]
CSF analysis. See [link]
CT. See [link]
CT angiography. See [link]
CTEPH (chronic thromboembolic pulmonary hypertension), [link]
Cullen’s sign, [link]
culture-negative endocarditis, [link]–[link]
culture(s)
of ascitic fluid, [link]
blood
in fever evaluation, [link]
in HIV-related enterocolitis evaluation, [link]
in infective endocarditis evaluation, [link]
in meningitis evaluation, [link]
in fever evaluation, [link]
in FUO evaluation, [link]
CUP (carcinoma of unknown primary), [link]
Cushing’s syndrome
hypertension due to, [link]
metabolic alkalosis due to, [link]
polycythemia due to, [link]–[link]
cutaneous disorders, eosinophilia due to, [link]
CVCs. See [link]
cyclosporine, hyperkalemia from, [link]
cystitis
recurrent
approach to patient with, [link]
treatment of, [link]–[link]
uncomplicated
approach to patient with, [link]
treatment of, [link]
cytogenetic studies, in CML evaluation, [link]
cytomegalovirus (CMV) infection
acute liver failure due to, [link]
bone marrow transplantation and, [link]
CD4 count and, [link]
esophagitis due to, [link]
FUO due to, [link]
HIV-related meningitis due to, [link]
polyradiculopathy due to, [link]
cytopenias, in FUO evaluation, [link]


D
dabigatran, for atrial fibrillation, [link]
Dacogen (decitabine), [link]
DAPT (dual antiplatelet therapy), [link]
dasatinib (Sprycel), in CML management, [link]
DDAVP (desmopressin), [link]
D-dimer assay, in pulmonary embolism evaluation, [link], [link]
death
pronouncement, [link]
responding to grief, [link]
signs of approaching, [link]
death rattle, [link]
decitabine (Dacogen), [link]
decubitus ulcers, [link]
deep venous thrombosis (DVT)
anticoagulation therapy for, [link]–[link]
hospital-acquired complications, [link]–[link]
hypercoagulable state evaluation, [link]
pulmonary embolism and, [link]
dehydration, polycythemia due to, [link]
delirium, [link]
delirium tremens, [link]
dementia
described, [link]
HIV-associated, [link]
depression, in dying patients, management of, [link]
descending aortic dissection, [link]
desmopressin (DDAVP), [link]
desquamating rashes, [link]
DGI (disseminated gonococcal infection), [link]
DHS (drug hypersensitivity syndrome), [link]–[link]
diabetes insipidus (DI), hypernatremia and, [link]
diabetes mellitus
nephrotic syndrome due to, [link]
perioperative medication management, [link]
diabetic ketoacidosis (DKA)
anion gap acidosis due to, [link]
approach to patient with, [link]
causes of, [link]
clinical manifestations of, [link]–[link]
definition, [link]
treatment of, [link]–[link]
diagnoses, continuum of, [link]
dialysis
for acute kidney injury, [link]
in hyperkalemia management, [link]
for salicylate toxicity, [link]
diaphragm, outside-in radiograph approach for, [link]
diarrhea
acute
approach to patient with, [link]–[link]
classification of, [link]
defined, [link]
in hospitalized patients, common causes of, [link]
treatment of, [link]
HIV-related enterocolitis, [link]
metabolic acidosis from, [link]
DIC. See [link]
diet
in acute diarrhea management, [link]
in ESLD management, [link]
in hyperkalemia management, [link]
differential diagnosis
continuum of diagnoses, [link]
systematic approach to, [link]–[link]
diffuse alveolar hemorrhage, massive hemoptysis and, [link]
diffusing capacity for carbon monoxide (DLCO), [link], [link]
diffusion defects, [link]
digoxin
for atrial fibrillation, [link]
in chronic HFrEF management, [link]
dihydropyridines, in angina management, [link]
dilated cardiomyopathies, [link]
diltiazem
in angina management, [link]
for atrial fibrillation, [link]
Dilute Russell’s viper venom time (dRVVT), [link]
diphenhydramine, for phenothiazine overdose, [link]
diphtheria, [link]
diphtheroids, [link]
dipyridamole, in angina evaluation, [link]
direct hepatotoxicity, [link]–[link]
direct oral anticoagulants (DOACs), [link], [link]
direct thrombin inhibitors, in pulmonary embolism management, [link]
disc(s), herniated, [link], [link]
disease-modifying antirheumatic drugs (DMARDs), [link]
disorganized thinking, [link]
dispensing errors, [link]
disseminated candidal disease, in HIV infected patients, [link]
disseminated gonococcal infection (DGI), [link]
disseminated intravascular coagulation (DIC)
acquired platelet dysfunction due to, [link]
acute leukemia and, [link]
in acute leukemia evaluation, [link]
bleeding disorder management, [link]
MAHA due to, [link]
in thrombocytopenia evaluation, [link]
distal symmetric peripheral neuropathies, [link]–[link]
distributive shock, [link]
diuretic(s)
in acute dyspnea management, [link]
in chronic HFrEF management, [link]
for dyspnea, [link]
in hyperkalemia management, [link]
hypokalemia and, [link]
diverticulosis, [link]
Dix-Hallpike test, [link]–[link]
dizziness, [link]
DKA. See [link]
DLCO (diffusing capacity for carbon monoxide), [link], [link]
DMARDs (disease-modifying antirheumatic drugs), [link]
DNR or DNAR (do not resuscitate) orders, [link]–[link]
DOACs (direct oral anticoagulants), [link], [link]
dobutamine, in ACS management, [link]
dobutamine stress echocardiography, in angina evaluation, [link]
dofetilide, for atrial fibrillation, [link]
do not resuscitate (DNR or DNAR) orders, [link]–[link]
Doppler echocardiography, in pulmonary hypertension evaluation, [link]
Doppler ultrasound
carotid, in stroke evaluation, [link]
compression, in pulmonary embolism evaluation, [link]
transcranial, in stroke evaluation, [link]
double-density sign, [link]
DPAHC (durable power of attorney for health care), [link]
DRESS (drug rash with eosinophilia and systemic symptoms), [link]–[link]
dronabinol, for nausea and vomiting, [link]
dronedarone, for atrial fibrillation, [link]–[link]
drug hypersensitivity syndrome (DHS), [link]–[link]
drug-induced orthostasis, [link]
drug overdose(s)
general approach to, [link]–[link]
prevalence of, [link]
specific toxic syndromes, [link]–[link]
drug rash with eosinophilia and systemic symptoms (DRESS), [link]–[link]
drug(s). See also specific types
acquired platelet dysfunction due to, [link]
acute diarrhea due to, [link]
acute liver failure due to, [link]–[link]
acute pancreatitis due to, [link]
administration records, preventing errors in, [link]–[link]
adverse drug events, [link]–[link]
aplastic anemia due to, [link]
ESLD due to, [link]
exanthems due to, [link]
hypercoagulable states due to, [link]
hyperkalemia from, [link]
hypertension due to, [link]
hypothyroidism due to, [link]
ILD due to, [link]
nephrotic syndrome due to, [link]
for non-pain symptoms in dying patients, [link]–[link]
for pain treatment in dying patients, [link]–[link]
pancytopenia due to, [link]
perioperative cardiovascular risk reduction, [link]–[link]
perioperative medication management, [link]–[link]
rashes from, [link]
thrombocytopenia due to, [link], [link]–[link]
dRVVT (Dilute Russell’s viper venom time), [link]
dual antiplatelet therapy (DAPT), [link]
Duke Activity Status Index, [link]
duloxetine, [link]
durable power of attorney for health care (DPAHC), [link]
DVT. See [link]
dying patients
anxiety, treating, [link]
approach to, [link]–[link]
communication with family, [link]–[link]
constipation, treating, [link]–[link]
after death, [link]
depression, treating, [link]
dyspnea, treating, [link]–[link]
fatigue, treating, [link]
general discussion, [link]
goals of care discussion, [link]–[link]
nausea and vomiting, treating, [link]
non-pain symptoms, treatment of, [link]–[link]
pain management, [link]–[link]
signs of approaching death, [link]
dysesthesia, [link]
dysfibrinogenemia, [link]
dyslipidemia, [link]
dyspnea
acute
approach to patient with, [link]
causes of, [link]
defined, [link]
treatment of, [link]
in dying patients, treating, [link]–[link]
dysuria
clinical manifestations of UTI, [link]
differential diagnosis of, [link]–[link]


E
ecchymoses, [link]
echocardiography
in infective endocarditis evaluation, [link]
in pulmonary hypertension evaluation, [link]
for syncope, [link]
eculizumab, in PNH management, [link]
edema
ESLD and, [link]
nephritic syndrome and, [link]
edoxaban, for atrial fibrillation, [link]
EEG (electroencephalogram), in seizure disorder evaluation, [link]
EGPA (eosinophilic granulomatosis with polyangiitis), [link], [link]
EKGs. See [link]
elective surgery, [link]
electrical cardioversion
for atrial fibrillation, [link], [link], [link]
for narrow, irregular tachyarrhythmias, [link]
electrocardiograms (EKGs)
for abdominal pain evaluation, [link]
in ACS evaluation, [link]–[link]
in angina evaluation, [link], [link]
atrial fibrillation, [link]
atrial flutter, [link]
atrial tachycardia, [link]
AVNRT and, [link]–[link]
in AVRT evaluation, [link]
bradyarrhythmias, [link]
in chest pain evaluation, [link]
hyperkalemia and, [link]
hypokalemia and, [link]
in infective endocarditis follow-up, [link]
interpretation of
axis, [link]–[link]
classic changes in selected conditions, [link]–[link]
hypertrophy, [link]–[link]
intervals, [link]–[link]
overview, [link]
Q waves, [link]
rate, [link]
rhythm, [link]
ST/T wave changes, [link]
multifocal atrial tachycardia, [link]
in pulmonary embolism evaluation, [link]
in pulmonary hypertension evaluation, [link]
in shock evaluation, [link]
sinus tachycardia, [link]
for syncope, [link]–[link]
for toxicologic emergencies, [link]
electroencephalogram (EEG), in seizure disorder evaluation, [link]
electrolyte panel, in acute leukemia evaluation, [link]
electrolyte replacement, in DKA management, [link]–[link]
electrophysiologic (EP) studies, for syncope, [link]
eltrombopag, in ITP management, [link]
embolism, pulmonary. See [link]
embolus(i), infective endocarditis and, [link]
emergency situations
hypertension related, [link]–[link]
mechanical ventilation in, [link]
surgery, [link]
emergent surface echocardiogram, [link]–[link]
emetics, [link]
emphysema, [link]
empiric therapy
for fever, [link]–[link]
for HIV-related esophagitis, [link]
for infective endocarditis, [link]–[link]
for meningitis, [link], [link]
for pneumonia, [link]
empyema, [link]
encephalopathy
acute liver failure and, [link]–[link], [link]
HIV-related, [link]–[link]
endocarditis, acute, [link]
endocrine disorders, pruritus due to, [link]
end-of-life care
anxiety, treating, [link]
approach to dying patient, [link]–[link]
communication with family, [link]–[link]
constipation, treating, [link]–[link]
after death, [link]
depression, treating, [link]
dyspnea, treating, [link]–[link]
fatigue, treating, [link]
general discussion, [link]
goals of care discussion, [link]–[link]
nausea and vomiting, treating, [link]
non-pain symptoms, treatment of, [link]–[link]
pain management, [link]–[link]
signs of approaching death, [link]
endoscopic retrograde cholangiopancreatography (ERCP), [link]
endoscopy
in FUO evaluation, [link]
in GI bleeding evaluation, [link], [link]
in HIV-related enterocolitis evaluation, [link]
in HIV-related esophagitis evaluation, [link]
end-stage liver disease (ESLD)
AKI due to, [link]
approach to patient with, [link]–[link]
causes of, [link]–[link]
clinical manifestations of, [link]
defined, [link]
treatment of, [link]–[link]
Enterococcus, [link], [link]
enterocolitis, HIV-related, [link]
eosinopenia, [link]
eosinophil-associated lung diseases, [link]
eosinophilia
causes of, [link]
defined, [link]
eosinophils, overview of, [link]
eosinophilic granuloma, [link]
eosinophilic granulomatosis with polyangiitis (EGPA), [link], [link]
eosinophils, overview of, [link]
EP (electrophysiologic) studies, for syncope, [link]
epidural hematoma, [link]
epidural hemorrhage, [link]
epilepsy
defined, [link]
epidemiology of, [link]
treatment of, [link]–[link]
Epstein-Barr virus, [link], [link]
eptifibatide, [link]
ERCP (endoscopic retrograde-cholangiopan creatography), [link]
erosive arthritis
CT in evaluation of, [link]
MRI in evaluation of, [link]
ultrasound in evaluation of, [link]
error disclosure, [link]
erysipelas, [link]
Erysipelothrix, [link]
erythema marginatum, [link]
erythema nodosum, [link]
erythrocyte sedimentation rate (ESR), in multiple myeloma evaluation, [link]
erythromelalgia, [link], [link]
erythropoietin, in MDS management, [link]
erythropoietin-secreting tumors, polycythemia due to, [link], [link]
Escherichia coli, [link]
ESLD. See [link]
esmolol, for atrial fibrillation, [link]
esophageal varices, bleeding, [link]–[link]
esophagitis, HIV-related, [link]–[link]
ESR (erythrocyte sedimentation rate), in multiple myeloma evaluation, [link]
essential hypertension, [link]–[link]
essential thrombocytosis (ET), [link], [link], [link]–[link]
ethanol abuse, [link]
ethylene glycol intoxication, [link]
euvolemic hypoosmolar hyponatremia, [link]
evaporative cooling, in fever management, [link]
event recorders, for syncope, [link]
exanthems
described, [link]–[link]
types of, [link]–[link]
excisional biopsy
in Hodgkin’s lymphoma evaluation, [link]
in non-Hodgkin’s lymphoma evaluation, [link]
exercise-based cardiac rehabilitation, in ACS management, [link]
exercise EKG, in angina evaluation, [link]
exercise stress echocardiography, in angina evaluation, [link]
exercise treadmill testing, for syncope, [link]
expected adverse reactions, [link]
expiratory flow rate, [link]
exploratory laparotomy, in FUO evaluation, [link]
extensive lateral wall myocardial infarction, [link]
extrahepatic biliary obstruction, [link]
extrapulmonary tuberculosis, [link]
extrapyramidal dystonic effects, [link]
exudative effusions, [link], [link]


F
FAB (French-American-British) classification of MDS, [link]
factitious thyrotoxicosis, [link]
factor deficiency, coagulation, [link], [link]
factor inhibitor, coagulation, [link], [link]
factor V Leiden mutation, [link]
failure to oxygenate, [link]
failure to ventilate, [link]
fall(s), [link]
familial hypocalciuric hypercalcemia (FHH), [link]
familial Mediterranean fever, [link]
family, communication during dying process, [link]–[link]
Fanconi’s anemia, [link]
fatigue, in dying patients, management of, [link]
fatty liver, [link], [link]
felodipine, in angina management, [link]
femoral central venous catheter placement, [link]–[link]
FENa (fractional excretion of sodium), [link]–[link]
ferritin
in acute liver failure evaluation, [link]
AOSD in, [link]
fertility, Hodgkin’s lymphoma effects on, [link]
FEUrea (fractional excretion of urea), [link]
FEV1 (forced expiratory volume in 1 second), [link], [link], [link]
FEV1/FVC ratio, [link], [link]
fever
acute leukemia and, [link]
in AOSD, [link]
approach to patient with, [link]–[link]
causes of, [link]
described, [link]
infective endocarditis and, [link], [link]
from meningitis, [link]
normal body temperature, [link]
rash and
approach to patient with, [link]–[link]
causes of, [link]–[link]
described, [link]
top-to-bottom approach, [link]
treatment of, [link]–[link]
fever of unknown origin (FUO)
approach to patient with, [link]–[link]
causes of, [link]–[link]
defined, [link]
FHH (familial hypocalciuric hypercalcemia), [link]
fibrinolysis, in ACS management, [link]–[link]
first-degree AV nodal block, [link]
flecainide, for atrial fibrillation, [link]
flexible bronchoscopy, in massive hemoptysis evaluation, [link]
flow-cycled modes, [link]
flow cytometry, in lymphocytosis evaluation, [link]
fluconazole, in HIV-related esophagitis management, [link]
fluid analysis, in ascites evaluation, [link]
fluid replacement
in AKA management, [link]
in DKA management, [link]–[link]
fluid resuscitation, in shock management, [link]
fluoroquinolones, in cystitis management, [link]
focal lesion, [link]
focal seizures, [link]
fondaparinux, in pulmonary embolism management, [link]
forced expiratory volume in 1 second (FEV1), [link], [link], [link]
forced vital capacity, [link]
forward heart failure, [link]
fosfomycin, in cystitis management, [link]
fosphenytoin, [link]
fractional excretion of sodium (FENa), [link]–[link]
fractional excretion of urea (FEUrea), [link]
Francisella tularensis, [link]
FRC (functional residual capacity), [link]
free wall rupture, from ACS, [link]
French-American-British (FAB) classification of MDS, [link]
fresh-frozen plasma, in bleeding disorder management, [link]
functional capacity, determining, [link]
functional residual capacity (FRC), [link]
fungal coverage, in meningitis management, [link]
fungal endocarditis, [link]
fungal esophagitis, HIV-related, [link]
fungal infections
bone marrow transplantation and, [link]
chronic meningitis due to, [link]
FUO due to, [link]
HIV-related meningitis due to, [link], [link]
infective endocarditis, [link]
pulmonary infiltrates in HIV, differential diagnosis of, [link]
splenomegaly due to, [link]
FUO. See [link]
furosemide
in ATN management, [link]
in ESLD management, [link]


G
gabapentin, [link]
Gaisböck’s polycythemia, [link]
ganciclovir, for HIV-related viral esophagitis, [link]
gastric lavage, [link]
gastrointestinal (GI) bleeding, acute
approach to patient with, [link]–[link]
causes of, [link]–[link]
classification of, [link]
definitions, [link]
gastrointestinal (GI) disease, clubbing due to, [link]
gastrointestinal system, manifestations of HIV infections in
described, [link]
enterocolitis, [link]
esophagitis, [link]–[link]
hepatobiliary disease, [link]–[link]
Gaucher’s disease, [link]
GCA (giant cell arteritis), [link], [link]–[link]
G-CSF. See [link]
general errors, [link]
generalized lymphadenopathy, [link], [link]
generalized seizures, [link]–[link]
GI (gastrointestinal) disease, clubbing due to, [link]
giant cell arteritis (GCA), [link], [link]–[link]
GI bleeding, acute. See [link]
Gitelman’s syndrome, [link]
Glanzmann’s thrombasthenia, [link], [link]
Gleevec (imatinib), in CML management, [link]
glomerular hematuria, [link]
glomerulonephritis
chronic, [link]
MPGN, [link]
postinfectious, [link]–[link]
glucocorticoid insufficiency, [link]
GM-CSF (granulocyte-macrophage colony-stimulating factor)
ILD and, [link]
in MDS management, [link]
goals of care discussion, [link]–[link]
gonococcal arthritis, [link]
Goodpasture’s syndrome, [link]
Gottron’s papules, [link]–[link], [link]–[link]
GPA. See [link]
graft-versus-host disease (GVHD), [link]
gram-negative bacilli, [link]
gram-negative cocci, [link]
gram-negative rods, [link]–[link]
gram-negative sepsis, [link]
gram-positive cocci, [link]
gram-positive rods, [link]–[link]
Gram stain with culture, in pleural effusion evaluation, [link]
granulocyte colony-stimulating factor (G-CSF)
in MDS management, [link]
in pancytopenia management, [link]
granulocyte-macrophage colony-stimulating factor (GM-CSF)
ILD and, [link]
in MDS management, [link]
granulomatosis with polyangiitis (GPA)
ILD due to, [link]
nephritic syndrome due to, [link]
vasculitis due to, [link]
granulomatous inflammation, [link]
Grey Turner’s sign, [link]
grief, responding to, [link]
growth factors, in MDS management, [link]
Guillain-Barré syndrome, [link]–[link]
Gupta risk index, [link]
gut decontamination, [link]–[link]
GVHD (graft-versus-host disease), [link]


H
H2-receptor antagonists, [link]
HACEK group organisms, [link]
Haemophilus influenzae, [link], [link], [link]
hallucinations, alcohol withdrawal, [link]
haloperidol, for nausea and vomiting, [link]
Hampton’s hump, [link]
HAP (hospital-acquired pneumonia), [link], [link], [link]
Hashimoto’s disease, [link]
HCAP (health care-associated pneumonia), [link], [link]
headaches
in FUO evaluation, [link]
from meningitis, [link]
head impulse test (HIT), [link]
health care-associated pneumonia (HCAP), [link], [link]
health literacy, [link]
heart, outside-in radiograph of, [link]
heart failure (HF)
acute, [link]–[link]
acute dyspnea and, [link]
approach to patient with, [link]
arrhythmias, [link]
classification schemes, [link]–[link]
clinical manifestations, [link]
defined, [link]
forward versus backward, [link]
HFmrEF, [link], [link]
HFrEF, [link], [link]–[link]
incidence, [link]
infective endocarditis complications, [link]
lift- versus right-sided, [link]–[link]
mortality rates, [link]
radiograph approach for, [link]
right-sided, ascites due to, [link], [link]
treatment of, [link]–[link]
heart failure with midrange ejection fraction (HFmrEF), [link], [link]
heart failure with preserved ejection fraction (HFpEF), [link], [link], [link]
heart failure with reduced ejection fraction (HFrEF), [link], [link]–[link]
heart transplantation, [link]
heated high-flow nasal cannula, in acute dyspnea management, [link]
heavy metals, nephrotic syndrome due to, [link]
heliotrope rash, [link]–[link], [link]–[link]
heliox, for obstructive lung disease, [link]
HELLP (Hemolysis, Elevated Liver enzymes, Low Platelets) syndrome, [link]
helminthic infections, eosinophilia due to, [link]
hemarthrosis, arthritis due to, [link]
hematemesis, [link]
hematochezia, [link]
hematogenous seeding, infective endocarditis and, [link]
hematologic disorders, pulmonary hypertension due to, [link]
hematuria, in FUO evaluation, [link]
hemochromatosis, [link]
hemodynamic status, in ACS evaluation, [link]–[link]
Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome, [link]
hemolytic anemia, [link]
hemolytic uremic syndrome (HUS), [link]
hemoptysis
approach to patient with, [link]
causes of, [link]
defined, [link]
in FUO evaluation, [link]
massive, [link]
nonmassive, [link]
hemorrhage
acute liver failure complications, [link]
epidural, [link]
liver failure complications, [link]
stroke due to, [link]–[link], [link]–[link]
hemorrhagic fevers, [link]
hemorrhagic transformation, stroke due to, [link]
Henoch-Schönlein purpura, [link]
heparin
in hypercoagulable state management, [link]
hyperkalemia from, [link]
in pulmonary embolism management, [link]
heparin-induced thrombocytopenia (HIT), [link]–[link]
heparin-induced thrombocytopenia and thrombosis (HITT), [link], [link]
hepatic encephalopathy, [link]
hepatic parenchymal disease, HIV-related, [link]
hepatic vein obstruction, acute liver failure due to, [link]
hepatic venoocclusive disease, [link]
hepatitis
acute, [link]
acute liver failure due to, [link], [link]
alcoholic, [link]–[link]
arthritis due to, [link]
autoimmune, [link], [link]
autoimmune diseases triggered by, [link]
chronic, [link], [link]
ESLD due to, [link]
nephritic syndrome due to, [link]
hepatobiliary disease, HIV-related, [link]–[link]
hepatocellular liver injury pattern, [link]–[link]
hepatomegaly, in Waldenström’s macroglobulinemia evaluation, [link]
hepatopulmonary syndrome, [link]
hepatorenal syndrome, [link]–[link], [link]
hereditary clubbing, [link]
herniated disc(s), [link], [link]
heroin, nephrotic syndrome due to, [link]
herpes virus infections
acute liver failure due to, [link]
bone marrow transplantation and, [link]
esophagitis due to, [link]
in HIV infected patients, [link]
HIV-related meningitis due to, [link]
HF. See [link]
HFmrEF (heart failure with midrange ejection fraction), [link], [link]
HFpEF (heart failure with preserved ejection fraction), [link], [link], [link]
HFrEF (heart failure with reduced ejection fraction), [link], [link]–[link]
hiccoughs
causes of, [link]
defined, [link]
treatment of, [link]
high bicarbonate syndromes, [link]
high-resolution computed tomography (HRCT), in ILD evaluation, [link]
hip fractures, [link]
histoplasmosis, [link], [link]
HIT (head impulse test), [link]
HIT (heparin-induced thrombocytopenia), [link]–[link]
HITT (heparin-induced thrombocytopenia and thrombosis), [link], [link]
HIV infection
CD4 counts, differential diagnoses according to, [link]–[link]
described, [link]
eosinophilia due to, [link]
FUO due to, [link], [link]
gastrointestinal manifestations of
described, [link]
enterocolitis, [link]
esophagitis, [link]–[link]
hepatobiliary disease, [link]–[link]
hepatic parenchymal disease, [link]
lymphadenopathy due to, [link]
neurologic manifestations of
described, [link]
encephalopathy, [link]–[link]
meningitis, [link]–[link]
myelopathy, [link]
peripheral neuropathy, [link]–[link]
space-occupying lesions, [link]–[link]
obstructive biliary tract disease, [link]
PCP and, [link]–[link]
pruritus due to, [link]
pulmonary infiltrates in, [link]
HIV test, [link]
Hodgkin’s lymphoma (HL), [link]–[link], [link]
Holter monitors, for syncope, [link]
hospice, [link]
hospital-acquired complications
ADE, [link]–[link]
catheter-associated UTI, [link]
C. difficile infection, [link]
CIN, [link]–[link]
CLABSI, [link]
falls, [link]
general errors, [link]
overview, [link]
pressure injury to skin, [link]
stress-related UGIB, [link]
VAP, [link]
VTE, [link]–[link]
hospital-acquired pneumonia (HAP), [link], [link], [link]
Hospital Compare website, [link]
hospitalization
acute diarrhea, common causes of, [link]
alcohol use and, [link]
pneumonia criteria for admission, [link]
Howell-Jolly bodies, [link]
HRCT (high-resolution computed tomography), in ILD evaluation, [link]
HUS (hemolytic uremic syndrome), [link]
hydration, in polycythemia management, [link]
hydrochlorothiazide, hypercalcemia due to, [link]
hydroxyurea
in CML management, [link]
in ET management, [link]
in PMF management, [link]
in PV management, [link]
in thrombocytosis management, [link]
hyperaldosteronism, primary, [link]
hypercalcemia
causes of, [link]–[link]
clinical manifestations of, [link]
definition, [link]
EKGs and, [link]
hypertension due to, [link]
in multiple myeloma evaluation, [link]
treatment of, [link]
in Waldenström’s macroglobulinemia evaluation, [link]
hypercapnic respiratory failure, [link]
hypercoagulable states
approach to patient with, [link]–[link]
causes of, [link]–[link]
clinical manifestations of, [link]
defined, [link]
pathogenesis, [link]
treatment of, [link]–[link]
hypereosinophilic syndrome, eosinophilia due to, [link]
hyperesthesia, [link]
hyperglycemia, from steroid administration, [link]
hyperhomocysteinemia, [link]
hyperimmunoglobulin G4 (hyper-IgG4) disease, [link], [link]
hyperkalemia
acute dialysis in management of, [link]
approach to patient with, [link]
causes of, [link]–[link]
clinical manifestations of, [link]–[link]
defined, [link]
described, [link]
EKG interpretation, [link], [link]
potassium excretion, decreased, [link]–[link]
with transcellular redistribution, [link]
treatment of, [link]–[link]
hyperkalemic periodic paralysis, [link]
hyperlipidemia, acute pancreatitis due to, [link]
hypernatremia
approach to patient with, [link]–[link]
clinical manifestations of, [link]
defined, [link]
described, [link]
treatment of, [link]
hyperosmolar hyponatremia, [link]
hyperparathyroidism, primary, [link]
hyperpigmentation, [link]
hyperproliferative normocytic anemia, [link]–[link]
hyperreninemic states, [link]
hypersensitivity pneumonitis, [link]
hypersplenism
pancytopenia due to, [link]
splenomegaly and, [link]
thrombocytopenia due to, [link]
hypertension
defined, [link]
emergencies, [link]–[link]
essential, [link]–[link]
nephritic syndrome and, [link]
secondary, [link]–[link]
urgencies, [link]
hypertensive encephalopathy, [link]
hyperthermia, [link]
hyperthyroidism, [link], [link]
hypertonic hyponatremia, [link]
hypertrophic osteoarthropathy, [link]
hypertrophy interpretation in EKGs, [link]–[link]
hyperviscosity
polycythemia and, [link]
in PV evaluation, [link]
in Waldenström’s macroglobulinemia evaluation, [link]
hypervolemic hypoosmolar hyponatremia, [link]
hypesthesia, [link]
hypoaldosteronism, [link]
hypocalcemia
causes of, [link]–[link]
clinical manifestations of, [link]
definition, [link]
described, [link]
EKGs interpretation, [link]
treatment of, [link]
hypoglycemia, [link], [link]
hypokalemia
acute liver failure and, [link], [link]
causes of, [link]–[link]
clinical manifestations of, [link]
defined, [link]
EKG interpretation, [link]
plasma potassium, maintenance of, [link]
potassium depletion and, [link]–[link]
with transcellular redistribution, [link]
treatment of, [link]
hypokalemic periodic paralysis, [link]
hypomagnesemia, [link]
hyponatremia
acute liver failure and, [link], [link]
antidiuretic hormone, action of, [link]
approach to patient with, [link]–[link]
clinical manifestations of, [link]
defined, [link]
in DKA evaluation, [link]
hyperosmolar, [link]
hypoosmolar, [link]
isoosmolar, [link]
SIADH, [link]
hypoosmolar hyponatremia, [link]
hypoparathyroidism, hypocalcemia due to, [link]–[link]
hypophosphatemia, acute liver failure and, [link], [link]
hypopituitarism, [link]
hypoproliferative normocytic anemia, [link]–[link]
hyporeninemic states, [link]
hypotension
in DKA evaluation, [link]
in hypocalcemia evaluation, [link]
hypothermia, in DKA evaluation, [link]
hypothyroidism
ascites due to, [link]
described, [link]–[link]
electrocardiogram changes, [link]
macrocytic anemia due to, [link]
hypoventilation, [link]
hypovolemia
nephrotic syndrome and, [link]
shock due to, [link]
syncope and, [link]
hypovolemic hypoosmolar hyponatremia, [link]
hypoxemia
clinical values, [link]
mechanisms of, [link]
in polycythemia evaluation, [link], [link]
pulmonary hypertension and, [link]
hypoxemic respiratory failure, [link]


I
IABP (intra-aortic balloon pump), in ACS management, [link]
ibuprofen, in fever management, [link]
ICD. See [link]
idiopathic aortic vasculitis, [link]
idiopathic interstitial pneumonia (IIP), [link]
idiopathic pulmonary fibrosis (IPF), [link]
idiosyncratic hepatotoxicity, [link]
IE. See [link]
If-channel inhibitor (ivabradine), in chronic HFrEF management, [link]–[link]
IFN-α‎. See [link]
IgA (immunoglobulin A) nephropathy, [link]
IIP (idiopathic interstitial pneumonia), [link]
ILD. See [link]
imatinib (Gleevec), in CML management, [link]
immobilization, hypercalcemia due to, [link]
immune complex disease, [link]
immune disorders, aplastic anemia due to, [link]
immune-mediated destruction, pancytopenia due to, [link]
immune thrombocytopenic purpura (ITP), [link], [link]–[link]
immunoelectrophoresis, in multiple myeloma evaluation, [link]
immunoglobulin A (IgA) nephropathy, [link]
immunologic disorders, eosinophilia due to, [link]
immunosuppressive agents
in aplastic anemia management, [link]
in ITP management, [link]–[link]
implantable cardiac defibrillator (ICD)
for CHF, [link]
after MI, [link]
for tachyarrhythmias related to ACS, [link]
for VT, [link]
implantable loop records, for syncope, [link]
incomplete bundle branch block, [link]
infection(s). See also [link]; [link]; [link]; [link]
acute diarrhea due to, [link]
acute liver failure and, [link], [link]
acute pancreatitis due to, [link]
aplastic anemia due to, [link]
arthritis due to, [link], [link]
catheter-associated urinary tract infection, [link]
C. difficile, [link]
central line-associated bloodstream infection, [link]
eosinophilia due to, [link]
ESLD due to, [link]
exanthems due to, [link]
HIV-associated myelopathy due to, [link]
hypocalcemia due to, [link]
liver failure complications, [link]
lymphadenopathy due to, [link], [link]
in multiple myeloma evaluation, [link]
nephrotic syndrome and, [link], [link]
pancytopenia due to, [link], [link]
pruritus due to, [link]
skin and soft tissue
animal bites, [link]–[link]
cellulitis, [link]–[link]
described, [link]
pyomyositis, [link]
spinal cord compression due to, [link], [link]
splenomegaly due to, [link]
thrombocytopenia due to, [link]
travel-related, [link]
infectious colitis, [link]
infective endocarditis (IE)
approach to patient with, [link]
causes of, [link]–[link]
clinical manifestations of, [link]
complications of, [link]
described, [link]
follow-up on, [link]
treatment of, [link]–[link]
inferior vena cava (IVC) filters
in hypercoagulable state management, [link]
in pulmonary embolism management, [link]
inferior vena cava obstruction, acute liver failure due to, [link]
inferior wall myocardial infarction, [link], [link]
inflammation, acute diarrhea due to, [link]
inflammatory arthritis
MRI in evaluation of, [link]
radionuclide bone scan in evaluation of, [link]
ultrasound in evaluation of, [link]
inflammatory bowel disease, [link]
inflammatory demyelinating polyneuropathy, [link]
inflammatory retiform purpura, [link]
influenza virus, [link]
informed consent for procedures, [link]
inherited cardiomyopathies, [link]
inherited clotting disorders, hypercoagulable states due to, [link]–[link]
inherited platelet dysfunction, [link]
initiation phase of ventilatory support, [link], [link]
inotropic agents, in ACS management, [link], [link]
INR (international normalization ratio), [link]
inspiration, in chest radiographs, [link]
inspired oxygen tension, [link]
insulin
in DKA management, [link]
in hyperkalemia management, [link], [link]
interferon-α‎ (IFN-α‎)
for CML, [link]
for ET, [link]
for PMF, [link]
international normalization ratio (INR), [link]
International Staging System, [link]
interstitial cystitis, [link]
interstitial infiltrates, [link]
interstitial lung disease (ILD)
approach to patient with, [link]
causes of, [link]
classification of, [link]
common features, [link]
interstitial nephritis, acute, [link], [link]
interval interpretation in EKGs, [link]–[link]
interventricular conduction delay, [link]
intra-abdominal infections, FUO due to, [link]
intra-aortic balloon pump (IABP), in ACS management, [link]
intracerebral hemorrhage, [link]
intraparenchymal hemorrhage, [link]–[link]
intravenous immunoglobulin (IVIG)
in ITP management, [link]
in peripheral neuropathy management, [link]
intravenous magnesium, in obstructive lung disease management, [link]
intravenous proton pump inhibitors, in GI bleeding management, [link]
intrinsic renal disease, hypertension due to, [link]
iodine-induced thyrotoxicosis, [link]
IPF (idiopathic pulmonary fibrosis), [link]
iron deficiency anemia, [link], [link], [link], [link]
irregular tachyarrhythmias
narrow, [link]
differential diagnosis, [link]
treatment of, [link]
wide, [link]–[link]
differential diagnosis, [link]–[link]
treatment of, [link]
ischemia(s)
gastrointestinal bleeding due to, [link]
myocardial, [link], [link]–[link]
ischemic disorders, [link]
ischemic infarction, [link], [link], [link]–[link]
isolated atrial fibrillation, [link]
isolated central nervous system vasculitis, [link]
isoniazid overdose, [link]
isoosmolar hyponatremia, [link]
isotonic hyponatremia, [link]
ITP (immune thrombocytopenic purpura), [link], [link]–[link]
ivabradine, in chronic HFrEF management, [link]–[link]
IVC filters. See [link]
IVIG (intravenous immunoglobulin)
in ITP management, [link]
in peripheral neuropathy management, [link]


J
JAK2 mutation assessment, [link], [link], [link]
JAK inhibitors, in PMF management, [link]
Janeway lesions, [link]
Jod-Basedow disease, [link]
joint effusions, ultrasound in evaluation of, [link]
joint fluid, laboratory testing of, [link]–[link]
Jones criteria, [link]–[link]
jugular venous pressure, [link]


K
Kaposi’s sarcoma, [link]
Kawasaki disease, [link]
Kayexalate, in hyperkalemia management, [link]–[link]
Kernig’s sign, [link]
ketoacidosis
alcoholic, [link], [link]–[link]
diabetic, [link], [link]–[link]
ketoconazole, in spinal cord compression management, [link]
kidney biopsy, [link]
kidney disease
chronic, hypercoagulable states due to, [link]
intrinsic, hypertension due to, [link]
metabolic acidosis and, [link]
kidney failure
acute liver failure complications, [link]–[link]
hypocalcemia due to, [link]
kidney injury, acute
approach to patient with, [link]–[link]
causes of, [link]–[link]
clinical manifestations of, [link]
defined, [link]
epidemiology of, [link]
treatment of, [link]–[link]
kidney transplantation, polycythemia due to, [link]
Klebsiella, [link]


L
laboratory testing
of blood, [link]
of joint fluid, [link]–[link]
in systemic autoimmune disease evaluation, [link]–[link]
lactate dehydrogenase (LDH)
in liver injury evaluation, [link]
in thrombocytopenia evaluation, [link]
lactic acidosis, [link]
LAD (left axis deviation), [link]–[link]
Laënnec’s cirrhosis, [link], [link], [link]
LAM (lymphangioleiomyomatosis), [link]
laparoscopy, in ascites evaluation, [link]
laparotomy, exploratory, in FUO evaluation, [link]
large-artery vasculitis, [link]–[link]
lateral view, [link]
lateral wall accessory pathway, [link]
LBBB (left bundle branch block), [link]
LDH. See [link]
lead reversal, [link]
left anterior fascicular block, [link]
left atrial abnormality, [link]
left axis deviation (LAD), [link]–[link]
left bundle branch block (LBBB), [link]
left posterior fascicular block, [link]
left-sided heart failure, [link]
left ventricular aneurysm, [link]
left ventricular assist devices, in ACS management, [link]
left ventricular hypertrophy (LVH), [link]
Legionella, [link]
leptospirosis, FUO due to, [link]
lesions
bony, in Waldenström’s macroglobulinemia evaluation, [link]
Janeway, [link]
lytic bone, in multiple myeloma evaluation, [link]
ocular, in systemic autoimmune diseases, [link]
oral, in systemic autoimmune diseases, [link]
skin, in systemic autoimmune diseases, [link]
space-occupying, HIV-related, [link]–[link]
leukapheresis, in CML management, [link]
leukemia
acute
approach to patient with, [link]–[link]
classification of, [link]–[link]
clinical manifestations of, [link]–[link]
complications associated with, [link]–[link]
described, [link]
epidemiology of, [link]
MDS and, [link]
risk factors for, [link]
treatment of, [link]–[link]
chronic eosinophilic, [link]
leukemoid reaction, [link]
leukocytosis
basophilia, [link]
definitions, [link]
described, [link]
lymphocytosis, [link]
monocytosis, [link]
neutrophilia, [link]
leukoerythroblastic smear, in pancytopenia evaluation, [link]
leukoerythroblastosis, [link], [link]
leukostasis, acute leukemia and, [link], [link]
levothyroxine, [link]
liberation phase of ventilatory support, [link], [link]
lidocaine, for VT, [link], [link]
life support, [link]
lightheadedness, [link]
Light’s criteria, [link]
likelihood ratio, [link]–[link]
lingular infiltrate, [link]
Listeria monocytogenes, [link], [link]
livedo reticularis, [link]
liver
core functions of, [link]
metastasis to, [link]–[link]
liver biopsy
in acute liver failure evaluation, [link]
in FUO evaluation, [link]
in HIV-related hepatobiliary disease evaluation, [link]
liver disease, chronic, macrocytic anemia due to, [link]
liver failure
approach to patient with, [link]–[link]
causes of, [link]–[link]
clinical manifestations of, [link]–[link]
definitions, [link]
treatment of, [link]–[link]
liver tests
abnormalities of, [link]
in bleeding disorder evaluation, [link]
described, [link]
in fever evaluation, [link]
general approach to, [link]–[link]
liver transplantation, [link]
living will, [link]
LMWH. See [link]
localized lymphadenopathy, [link]
Löfgren’s syndrome, [link]
lone atrial fibrillation, [link]
long-acting nitrates, [link]
long-standing persistent atrial fibrillation, [link]
loop diuretics, [link]
loop recorders, for syncope, [link]
lorazepam, [link]–[link]
low back pain, in infective endocarditis, [link]
low bicarbonate syndromes, [link]
lower extremity testing, noninvasive, in pulmonary embolism evaluation, [link]
lower GI tract bleeding, [link]
low inspired oxygen tension, [link]
low-molecular-weight heparin (LMWH)
in hypercoagulable state management, [link]
in pulmonary embolism management, [link]
lumbar puncture
in meningitis evaluation, [link]–[link]
procedure for, [link]–[link]
in stroke evaluation, [link]
lung auscultation, [link]
lung disease(s)
obstructive versus restrictive, [link]
pulmonary hypertension and, [link]
lung expansion maneuvers, [link]
lung(s)
in chest pain evaluation, [link]
examination of, shock and, [link]
metastasis to, [link]–[link]
outside-in radiograph approach for, [link]
perioperative pulmonary risks, [link]–[link]
pulmonary function tests, [link]
LVH (left ventricular hypertrophy), [link]
Lyme disease
FUO due to, [link]
rashes from, [link]
lymphadenopathy
approach to patient with, [link]–[link]
in chest radiographs, [link]
defined, [link]
in FUO evaluation, [link]
treatment of, [link]
lymphangioleiomyomatosis (LAM), [link]
lymphatic obstruction, ascites due to, [link], [link]
lymphocytic pleocytosis, [link], [link]–[link]
lymphocytosis, [link]
lymphoma(s)
classification of, [link]
defined, [link]
in HIV infected patients, [link]
Hodgkin’s, [link]–[link]
lymphadenopathy due to, [link], [link]
MALT, [link]
non-Hodgkin’s, [link]–[link]
primary CNS, [link]
lymphoproliferative disease, Sjögren’s syndrome and, [link]
lytic bone lesions, in multiple myeloma evaluation, [link]


M
M (monoclonal) protein, [link]
MAC infections. See [link]
macrocytic anemia, [link]
macules, [link]
maculopapular rash, [link]
magnesium
in alcohol withdrawal management, [link]
depletion, metabolic alkalosis due to, [link]
intravenous, in obstructive lung disease management, [link]
magnesium replacement, in DKA management, [link]
magnetic resonance angiography (MRA), in stroke evaluation, [link]
magnetic resonance imaging (MRI)
in arthritis evaluation, [link]
in HIV-related meningitis evaluation, [link]
in polyneuropathy evaluation, [link]
in seizure disorder evaluation, [link]
in space-occupying lesion evaluation, [link]
in spinal cord compression evaluation, [link]
MAHA. See [link]
maintenance phase of ventilatory support, [link]
maintenance therapy, in acute leukemia management, [link], [link]
malaria, FUO due to,